Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC

Launched by UNIVERSITY HOSPITAL, GHENT · Dec 22, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at the cells in the abdominal area of patients with colorectal cancer that has spread to the peritoneum, which is the lining of the abdomen. By studying these cells, researchers hope to learn more about how this type of cancer behaves and how it can be treated. The trial is currently recruiting patients who are scheduled to undergo a specific type of surgery called CRS (Cytoreductive Surgery) combined with HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for colorectal cancer that has spread to the peritoneum.

To be eligible for this trial, participants must be planning to have this surgery and should not have had a previous HIPEC or a related treatment called PIPAC. This means that the trial is open to any adult, regardless of gender, who meets these criteria. If you decide to participate, you can expect to provide samples during your surgery, which will help researchers gain insights into the cancer. This information could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing CRS+HIPEC for PC of colorectal origin
• Exclusion Criteria:
• • Previous HIPEC/PIPAC